Abstract:Abstract Background: Communication between cancer cells and surrounding cells in the tumor microenvironment (TME) is critical for tumor metastasis. There has been an increasing focus on how tumor-derived extracellular vesicles (EVs) contribute to the complex intracellular communications within the TME. More recent characterizations in both mice and humans have demonstrated that expression of the immune checkpoint molecule, programmed death ligand-1 (PD-L1) on EVs contributes to systemic immunosuppression, higher overall tumor burdens, and decreased survival of a variety of cancer types. In ovarian carcinoma, macrophages are reprogrammed toward pro-tumorigenic phenotypes, including the release of anti-inflammatory cytokines and expression of immunosuppressive molecules such as arginase-1 and PD-L1. However, a detailed mechanism that explains how tumor-derived EVs induce immunosuppressive phenotype in macrophages is necessary to develop novel immunotherapy strategies for advanced ovarian cancer treatment. The present study aimed to examine the effect of EVs derived from ovarian cancer cells on macrophage functions. Methods: We isolated murine peritoneal macrophages from naïve C57BL/6 female mice and co-cultured the macrophages with EVs derived from ovarian cancer (ID8-Trp53-/-Brca2-/-) cell lines. The expression of PD-L1, CD206, interleukin-6 (IL-6), and other inflammatory cytokines on EVs treated macrophages was evaluated using flow cytometry and a cytokine array kit. Further, we created Rab27aKO ID8 cell lines to generate ovarian cancer in vivo mouse models for studying the effect of exogenous EVs on the immunosuppressive ability of macrophages and tumor progression. Results: Our results indicate that EVs uptake efficiency of macrophages is higher than fibroblast, endothelial, and mesothelial cells. We found that tumor-derived EVs can significantly upregulate the expressions of PD-L1, CD206, and IL-6 on macrophages to support tumor growth. Treatment of macrophages with EVs also decreased their phagocytic ability. In addition, our data show that in the Rab27aKO ovarian cancer in vivo mouse model, intravenous injection of tumor-derived EVs increased the tumor burden, metastasis, and ascites accumulation as compared to PBS control. EVs treatment increased the infiltration of tumor-associated macrophages (TAM) in ascites. We also found increased expression of PD-L1 and CD206 on TAM isolated from ascites. Conclusion: We uncover a tumor-promoting role of ovarian cancer-derived EVs on reprogramming TAM towards pro-tumor phenotype. Our data suggest that tumor-derived EVs contribute to the formation of an immunosuppressive microenvironment to promote ovarian cancer growth. Citation Format: Sonam Mittal, Ishaque Pulikkal Kadamberi, Prachi Gupta, Sudhir Kumar, Jasmine George, Anjali Geethadevi, Pradeep Chaluvally-Raghavan, Sunila Pradeep. Tumor-derived extracellular vesicles induce macrophages immunosuppressive polarization to promote ovarian cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2321.

Kynurenine in IDO1high cancer cell-derived extracellular vesicles promotes angiogenesis by inducing endothelial mitophagy in ovarian cancer

Extracellular Vesicles from Ipsc-Mscs Alleviate Chemotherapy-Induced Mouse Ovarian Damage Via the ILK-PI3K/AKT Pathway

microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways

Ovarian cancer derived extracellular vesicles promote the cancer progression and angiogenesis by mediating M2 macrophages polarization

Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance

Tumor-Derived Extracellular Vesicles Promote Activation of Carcinoma-Associated Fibroblasts and Facilitate Invasion and Metastasis of Ovarian Cancer by Carrying miR-630

Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis

Cancer EV stimulate endothelial glycolysis to fuel protein synthesis via mTOR and AMPKα activation

Extracellular vesicles remodel tumor environment for cancer immunotherapy

Extracellular Vesicle-Mediated Mitochondrial Reprogramming in Cancer

Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications

Abstract 2321: Tumor-derived extracellular vesicles induce macrophages immunosuppressive polarization to promote ovarian cancer progression

Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion

Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells

Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer

Colorectal Cancer Cell-Derived Extracellular Vesicles Promote Angiogenesis Through JAK/STAT3/VEGFA Signaling

Extracellular vesicle-derived miR-320a targets ZC3H12B to inhibit tumorigenesis, invasion, and angiogenesis in ovarian cancer

Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling

Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC

miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6

Extracellular Vesicles in Ovarian Cancer: From Chemoresistance Mediators to Therapeutic Vectors